Safety profiles of iron chelators in young patients with haemoglobinopathies.
Eur J Haematol
; 98(3): 198-217, 2017 Mar.
Article
en En
| MEDLINE
| ID: mdl-27893170
ABSTRACT
BACKGROUND:
This review describes the safety of deferoxamine (DFO), deferiprone (DFP), deferasirox (DFX) and combined therapy in young patients less than 25 yr of age with haemoglobinopathies.METHODS:
Searches in electronic literature databases were performed. Studies reporting adverse events associated with iron chelation therapy were included. Study and reporting quality was assessed using AHRQ Risk of Bias Assessment Tool and McMaster Quality Assessment Scale of Harms. Prospective clinical studies were pooled in a random-effects meta-analysis of proportions.RESULTS:
Safety data of 2040 patients from 34 studies were included. Ninety-two case reports of 246 patients were identified. DFX (937 patients) and DFP (667 patients) possess the largest published safety evidence. Fewer studies on combination regimens are available. Increased transaminases were seen in all regimens (3.9-31.3%) and gastrointestinal disorders with DFP and DFX (3.7-18.4% and 5.8-18.8%, respectively). Therapy discontinuations due to adverse events were low (0-4.1%). Reporting quality was selective and poor in most of the studies.CONCLUSION:
Iron chelation therapy is generally safe in young patients, and published data correspond to summary of product characteristics. Each iron chelation regimen has its specific safety risks. DFO seems not to be associated with serious adverse effects in recommended doses. In DFP and DFX, rare, but serious, adverse reactions can occur. Data on combined therapy are scarce, but it seems equally safe compared to monotherapy.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Quelantes del Hierro
/
Sobrecarga de Hierro
/
Hemoglobinopatías
Tipo de estudio:
Prognostic_studies
/
Systematic_reviews
Idioma:
En
Revista:
Eur J Haematol
Año:
2017
Tipo del documento:
Article
País de afiliación:
Alemania